Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

CNBX Pharmaceuticals (CNBX) EBIT Margin (2016 - 2024)

CNBX Pharmaceuticals (CNBX) has disclosed EBIT Margin for 11 consecutive years, with 507.98% as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, EBIT Margin changed N/A year-over-year to 507.98%, compared with a TTM value of 1102.63% through Nov 2024, down 95121.0%, and an annual FY2024 reading of 448.31%, down 22124.0% over the prior year.
  • EBIT Margin was 507.98% for Q1 2024 at CNBX Pharmaceuticals, down from 192.2% in the prior quarter.
  • Across five years, EBIT Margin topped out at 1361.33% in Q2 2022 and bottomed at 66134.96% in Q1 2020.
  • Average EBIT Margin over 4 years is 14921.19%, with a median of 507.98% recorded in 2024.
  • Peak annual rise in EBIT Margin hit 1721654bps in 2020, while the deepest fall reached -2751225bps in 2020.
  • Year by year, EBIT Margin stood at 30390.26% in 2020, then surged by 95bps to 1596.75% in 2022, then surged by 88bps to 192.2% in 2023, then plummeted by -164bps to 507.98% in 2024.
  • Business Quant data shows EBIT Margin for CNBX at 507.98% in Q1 2024, 192.2% in Q4 2023, and 161.5% in Q3 2023.